Alignment Healthcare (NASDAQ:ALHC) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Alignment Healthcare (NASDAQ:ALHC) posted its quarterly earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10, FiscalAI reports. Alignment Healthcare had a negative net margin of 0.57% and a negative return on equity of 16.23%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion.

Here are the key takeaways from Alignment Healthcare’s conference call:

• Achieved strong growth — 25% membership growth to 236,300 in Q4 and full‑year revenue of $3.9B (46% YoY), with January 2026 membership rising to 275,300 (31% YoY).
• Meaningful margin progress — the company swung from roughly breakeven in 2024 to $110M adjusted EBITDA in 2025 and provided 2026 adjusted EBITDA guidance of $133M–$163M.
• Replicable ex‑California expansion — ex‑CA membership more than doubled to ~38,000 (16% of total), backed by multiple 4–5 star plans and management targeting long‑term scale toward ~1 million members.
• Reimbursement and policy risk — the 2027 advance rate notice and potential CMS changes (skin‑substitute offsets, V28 phase‑in, chart‑review rules) create a flatter rate environment that could pressure industry margins despite the company’s stated limited exposure.

Alignment Healthcare Stock Up 1.4%

ALHC stock traded up $0.29 during trading on Thursday, reaching $20.42. The stock had a trading volume of 2,603,198 shares, compared to its average volume of 2,717,012. Alignment Healthcare has a one year low of $11.63 and a one year high of $23.87. The company’s 50 day moving average is $21.01 and its two-hundred day moving average is $18.47. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 1.99. The company has a market capitalization of $4.09 billion, a price-to-earnings ratio of -170.17, a P/E/G ratio of 4.99 and a beta of 1.16.

Insider Buying and Selling at Alignment Healthcare

In other Alignment Healthcare news, President Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $20.63, for a total value of $618,900.00. Following the sale, the president owned 997,015 shares of the company’s stock, valued at approximately $20,568,419.45. The trade was a 2.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Andreas P. Wagner sold 22,238 shares of Alignment Healthcare stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $20.47, for a total transaction of $455,211.86. Following the completion of the sale, the insider directly owned 169,805 shares in the company, valued at $3,475,908.35. This trade represents a 11.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 2,125,938 shares of company stock valued at $41,799,570 in the last ninety days. 7.00% of the stock is owned by corporate insiders.

Institutional Trading of Alignment Healthcare

Several hedge funds have recently made changes to their positions in the company. Summit Securities Group LLC purchased a new stake in Alignment Healthcare in the 4th quarter worth about $26,000. Parallel Advisors LLC lifted its holdings in Alignment Healthcare by 87.7% during the 4th quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock worth $33,000 after purchasing an additional 773 shares in the last quarter. Larson Financial Group LLC bought a new stake in shares of Alignment Healthcare during the third quarter valued at about $33,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Alignment Healthcare in the third quarter worth about $53,000. Finally, Wexford Capital LP purchased a new position in Alignment Healthcare during the third quarter valued at approximately $164,000. 86.19% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Robert W. Baird set a $28.00 price objective on Alignment Healthcare in a research note on Friday, January 30th. Barclays lifted their target price on Alignment Healthcare from $13.00 to $18.00 and gave the stock an “equal weight” rating in a report on Friday, October 31st. JPMorgan Chase & Co. boosted their price target on Alignment Healthcare from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Piper Sandler raised their price objective on shares of Alignment Healthcare from $20.00 to $30.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 6th. Finally, TD Cowen increased their target price on shares of Alignment Healthcare from $18.50 to $25.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.95.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.